ONZIMA VENTURES PLC - Update on Investment

Onzima Ventures PLC

("Onzima" or the "Company")

Investee company N4 Pharma announces formation of scientific advisory panel

N4 Pharma Limited (“N4 Pharma”), in which Onzima holds a 49% equity stake, has announced that its intellectual property partner OPAL IP has formed a scientific advisory panel to provide advice and guidance on N4 Pharma’s reformulation projects, the first of which is its reformulation of sildenafil.

The panel is made up of Professor Karrar Khan, formerly Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll, Doctor David Templeton, an expert in pharmacokinetics and translational science, and Doctor Sean McCrossen, an expert in pharmaceutical development.

N4 Pharma CEO Nigel Theobald commented:

“This is a very strong advisory panel which together brings over 90 years’ experience to our development programs. It will be a huge asset to help make sure that our reformulations meet the requirements of industry and the regulators and we are delighted that OPAL IP has been able to put together such a strong team.”

For further information please contact:    

Onzima Ventures PLC                                                  Tel:  [phone]
Gavin Burnell, Luke Cairns

Nominated Adviser
Cairn Financial Advisers LLP                                        Tel:  [phone]       
Sandy Jamieson, Liam Murray

Broker
Peterhouse Corporate Finance Limited                           Tel:  [phone]   
Guy Miller, Lucy Williams

Copyright er 6 PR Newswire